Cymabay Therapeutics
CBAY
CBAY was delisted on the 21st of March, 2024.
118 hedge funds and large institutions have $755M invested in Cymabay Therapeutics in 2018 Q2 according to their latest regulatory filings, with 45 funds opening new positions, 36 increasing their positions, 28 reducing their positions, and 34 closing their positions.
32% more first-time investments, than exits
New positions opened: 45 | Existing positions closed: 34
30% more call options, than puts
Call options by funds: $640K | Put options by funds: $491K
29% more repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 28
21% more capital invested
Capital invested by funds: $627M → $755M (+$129M)
10% more funds holding
Funds holding: 107 → 118 (+11)
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$36.1M |
| 2 |
EAM
Eagle Asset Management
St Petersburg,
Florida
|
+$25.8M |
| 3 |
CTA
Carillon Tower Advisers
St. Petersburg,
Florida
|
+$18.1M |
| 4 |
ACA
Avoro Capital Advisors
New York
|
+$16M |
| 5 |
State Street
Boston,
Massachusetts
|
+$13.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$39.7M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
-$12.5M |
| 3 |
BC
Boxer Capital
San Diego,
California
|
-$7.75M |
| 4 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$7.14M |
| 5 |
Goldman Sachs
New York
|
-$4.78M |
CBAY Hedge Fund Activity: Q2 2018 in Review
118 of the 4,385 institutional investors tracked by Wall St. Rank reported a position in Cymabay Therapeutics (CBAY) for Q2 2018, worth a combined $755M — up 21% from $627M a quarter earlier.
Buyers outnumbered sellers: 45 funds opened new CBAY positions and 34 closed out — a net gain of 11 holders — while 36 added to existing stakes and 28 trimmed.
The largest buyer was BlackRock, adding an estimated $36.1M. The largest seller was Fidelity Investments, cutting an estimated $39.7M.
- 118 institutional investors held Cymabay Therapeutics (CBAY) as of Q2 2018, up from 107 in Q1 2018.
- Funds reported $755M of Cymabay Therapeutics stock for Q2 2018, up 21% quarter-over-quarter.
- 45 funds opened new Cymabay Therapeutics positions in Q2 2018 and 34 closed out, a net change of +11 holders.
- The largest Cymabay Therapeutics buyer in Q2 2018 was BlackRock, an estimated $36.1M added.
- The largest Cymabay Therapeutics seller in Q2 2018 was Fidelity Investments, an estimated $39.7M sold.
Based on aggregated 13F filings for Q2 2018.